|
Important research into gestational trophoblastic disease
(GTD) is being done right now in many university hospitals, medical
centers, and other institutions around the country. Each year,
scientists find out more about what causes the disease and how to
improve treatment.
Causes of GTD
Researchers are studying cells of GTD to learn more about how
these tumors develop. Discoveries about chromosome abnormalities of
complete and partial moles have helped explain the causes of these
types of GTD. These discoveries have been applied to developing lab
tests that can help identify these 2 types of moles (partial vs.
complete) when routine microscopic analysis does not yield a clear
answer.
Epidemiology
Researchers often collect data on how often various forms of
cancer occur in different parts of the world and whether these diseases
are becoming more or less common. This often provides clues about risk
factors and ideas for prevention. Earlier studies suggested that
choriocarcinoma and GTDs were 5 to 10 times more common in Asia than in
Europe and North America. More recent information indicates that the
difference is no greater than double and may be even less, and that the
original estimates were likely biased by differences in the way births
are recorded in different countries.
Staging and prognosis
Newer and more sensitive tests are now able to more accurately
determine blood human chorionic gonadotropin (HCG) levels than in the
past. Scientists have developed a blood test for a form of HCG known as
hyperglycosylated HCG. Early studies suggest that this blood test may
help separate patients with active GTD that need treatment from those
who have elevated HCG levels but don't truly have GTD, and therefore
may not require therapy. More studies are needed to confirm this.
Improvements in the staging systems and prognostic
classification systems are making it easier for doctors to recognize
which patients will benefit from which treatments.
Treatment
In recent years, a number of studies have shown the value of
using combination chemotherapy for high-risk metastatic GTD, such as
the EMA-CO and EMA-EP regimens. The excellent results with these
regimens have made them treatments of choice in many institutions.
Newer chemotherapy drugs including pemetrexed, ifosfamide,
paclitaxel, and gemcitabine are also being studied for use in this
disease, as are several new combinations of drugs. Some of these are
already in use in women whose GTD doesn't respond to other treatments.
For tumors that are resistant to standard chemotherapy doses,
doctors are studying the use of high-dose chemotherapy followed by a
stem cell transplant to restore the patient's bone marrow. Some very
early results have been promising, but more research is needed.
Researchers are also studying ways to give the usual
chemotherapy drugs with new schedules that might be more effective,
cause less severe side effects, and/or be more convenient for patients.
Last Medical Review: 10/13/2009
Last Revised: 10/13/2009
|
